NICE stiff-arms Roche melanoma drug once again
Roche ($RHHBY) tried to sway the U.K.'s cost-effectiveness watchdogs toward its targeted melanoma drug Zelboraf. But it failed. The National Institute for Health and Clinical Excellence stuck to its rejection.
UPDATED: Groundbreaking cancer study highlights potential immunotherapy for melanoma
Researchers have opened a new front in the war on deadly skin cancer. With their groundbreaking finding that the interleukin-9 molecule stymies melanoma growth in mice, the researchers have uncovered a potential new way to harness immune activity to combat cancer.
Bristol turns to blockbuster pipeline as Plavix goes generic
With clot-buster Plavix facing generic competition, the company is banking on some more wins in its pipeline to replace revenue from declining sales of its top seller.
BMS delivers sales, profit growth in Plavix's final quarter
All eyes are on new and forthcoming drugs as Bristol-Myers Squibb reports a 12% increase in first-quarter profits.
Cancer immunotherapy partners face big test with Phase III program
Merck KGaA and Oncothyreon ($ONTY) will learn soon whether their lung cancer vaccine has a shot at being one of the next bright lights in the cancer immunotherapy arena, with an interim analysis set
Bristol CEO touts successful biopharma blitz after big hep C play
Bristol-Myers Squibb ($BMY) mounted an enviable makeover from a diversified company to a biopharma force over the past several years, with the famed "String of Pearls" strategy advanced to buy
New Teva CEO expected to replicate "string of pearls" deal strategy
Over the past two years, Bristol-Myers Squibb ($BMY) has been widely lionized for its successful "string of pearls" approach to drug development. Now one of the chief authors of the strategy is
BMS sales up 8%, thanks to drugs new and old
Here's some good news about Bristol-Myers Squibb's ($BMY) third-quarter results: Plavix sales rose 8% to $1.79 billion. Here's some bad news: Plavix sales rose by 8%. The blood thinner goes off
NICE on BMS' Yervoy: The cost is too darn high
The breakthrough melanoma drug from Bristol-Myers Squibb ($BMY) isn't enough of a breakthrough for the U.K.'s cost-effectiveness watchdogs--at least not at its current price point. The...
Breakthrough meds deliver the goods for BMS, Vertex
Fear not, pharma. There really might be hope ahead. Or such is the feeling among analysts chuffed by the early success of three new drugs. You know the ones: Bristol-Myers Squibb's melanoma drug